Immune Checkpoint Inhibitors: Altering the Landscape of Treatment in Hepatobiliary Cancers

Gain insight into the emerging use of immunotherapy in the treatment of hepatobiliary cancers including HCC and BTCs with an expert-presented webcast and downloadable slidesets.

Share

Program Content

Activities

ICIs in HCC
Immune Checkpoint Inhibitors: Altering the Landscape of Treatment in Hepatobiliary Cancers
Multimedia
Congratulations: You achieved a completion on 04/09/2022

Released: July 27, 2021

Expires: July 26, 2022

Activities

ICIs for Advanced HCC
Immune Checkpoint Inhibitors for Advanced HCC
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 17, 2021

Expires: June 16, 2022

ICIs for BTC and Early HCC
Immune Checkpoint Inhibitors for Early-Stage HCC and Advanced BTC
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 17, 2021

Expires: June 16, 2022

<i>EP</i>: ICIs for Hepatobiliary
ExpressPoints: Immune Checkpoint Inhibitors: Altering the Landscape of Treatment in Hepatobiliary Cancers
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 18, 2021

Expires: June 17, 2022

Faculty

cover img faculity

Lipika Goyal, MD, MPhil

Associate Professor in Medicine
Director of Gastrointestinal Oncology
Stanford School of Medicine
Palo Alto, California

cover img faculity

Kate MacDougall

cover img faculity

Amit G. Singal, MD, MS

Chief of Hepatology
Medical Director
, Liver Tumor Program
Professor, Department of Internal Medicine
UT Southwestern Medical Center
Dallas, Texas

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

AstraZeneca